Premium
Use of big data for drug development and for public and personal health and care
Author(s) -
Leyens Lada,
Reumann Matthias,
Malats Nuria,
Brand Angela
Publication year - 2017
Publication title -
genetic epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.301
H-Index - 98
eISSN - 1098-2272
pISSN - 0741-0395
DOI - 10.1002/gepi.22012
Subject(s) - big data , exploit , health care , data science , variety (cybernetics) , analytics , work (physics) , drug development , public health , open data , public relations , business , computer science , medicine , political science , drug , engineering , data mining , computer security , nursing , mechanical engineering , artificial intelligence , psychiatry , world wide web , law
ABSTRACT The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.